Exhibit 10.4.4 




Confidential portions of this
document have been omitted and filed separately with the Commission. The omitted portions
have been marked as follows: “***”. 




CONSENT AND AGREEMENT 



        This
Consent and Agreement (this “Agreement”) is entered into as of July 9, 2004 between Par
Pharmaceutical, Inc. (“Par”) and Quintiles Ireland Limited (“QIreland”). 



Recitals 



        A.
  Par and Bioglan Pharma Inc. (now known as BPI New Corp., “BPI”) entered
  into the Distribution Agreement dated December 27, 2000 (the “Original
  Agreement”) regarding a pharmaceutical product currently marketed in the
  United States as Adoxa®; 



        B.
Par, BPl and QIreland entered into the Assignment of Distribution Agreement dated March
22, 2002 (the “First Amendment”), pursuant to which BPI assigned to QIreland the Original
Agreement, and the parties amended certain provisions of the Original Agreement; 



        C.
Par and QIreland entered into the Second Amendment to Distribution Agreement and First
Amendment to Assignment of Distribution Agreement dated September 11, 2003 (the “Second
Amendment”); 



        D.
Par and QIreland entered into the Third Amendment to Distribution Agreement dated April
13, 2004 (the “Third Amendment”) (the Original Agreement, as amended by the First
Amendment, the Second Amendment and the Third Amendment, is referred to in this Agreement
as the “Distribution Agreement”); 



        E.
QIreland and Bioglan Pharmaceuticals Company, an affiliate of QIreland, plan to transfer
and sell certain assets (the “Sale”) to BDY Acquisition Corp., a Delaware corporation and
wholly owned subsidiary of Bradley Pharmaceuticals, Inc., a Delaware corporation listed
on the New York Stock Exchange (the “Buyer”); 



        F.
In connection with the Sale, QIreland has requested, in accordance with Section 11.8 of
the Distribution Agreement, that Par consent to the transfer of the Distribution
Agreement to the Buyer and agree to certain matters as set forth in this Agreement; and 



        G.
Par has determined that such consent and agreement would benefit Par and accordingly Par
wishes to consent and agree to the transfer of the Distribution Agreement to Buyer and to
such other matters as are set forth in this Agreement. 



        NOW,
THEREFORE, the parties agree as follows: 



        (1)
Par hereby consents, acknowledges and agrees that: 



                (a)
  QIreland may assign and transfer all of its rights and obligations under the
  Distribution Agreement to the Buyer. Upon the effective date of such assignment
  and transfer (the “Assignment Date”): 



	   	
                           (i)  	the
Buyer shall be responsible for all                                     obligations under
the Distribution                                     Agreement, arising after the
Assignment                                     Date; 








	 	
	 













	   	
                          (ii)  	the
Buyer shall have and enjoy all the rights                                   and benefits
of QIreland under the                                   Distribution Agreement; 






	   	
                         (iii)  	QIreland
shall have no responsibility for any                                   obligations under
the Distribution Agreement                                   arising after the Assignment
Date; and 






	   	
                          (iv)  	QIreland
shall cease to be a party, and Buyer                                   shall become a
party, to the Distribution                                   Agreement with respect to
all obligations                                   under the Distribution Agreement
arising after                                   the Assignment Date; 






                (b)
Notwithstanding Section 11.8 of the Original Agreement, the Buyer shall be entitled to
assign and transfer any and all of its rights and obligations under the Distribution
Agreement, without Par’s consent, to an affiliate of the Buyer, but no such assignment or
transfer shall relieve the Buyer of any of, and the Buyer shall remain responsible for,
its obligations under the Distribution Agreement; 



                (c)
Prior to or on the Assignment Date, QIreland may assign or transfer any and all of its
rights and obligations under the Distribution Agreement to an affiliate of QIreland and
such party or parties may assign or transfer such rights and obligations to the Buyer,
which shall have the same effect as if QIreland had assigned such rights and obligations
to the Buyer as described in Section 1(a) above; and 



                (d)
The Distribution Agreement constitutes all of the agreements, arrangements or
understandings with respect to the subject matter thereof; the Distribution Agreement has
not been amended or modified; the Distribution Agreement is in full force and effect and,
to the knowledge of Par, QIreland is in compliance with the Distribution Agreement and no
breach or default has occurred thereunder, and no event has occurred and no circumstance
exists that, with the passage or lapse of time or the giving of notice, or both, would
constitute a breach or default. 



        (2)
Prior to or following the Assignment Date, each party agrees to execute and deliver such
other agreements, documents and instruments, and to do and take such other acts or
actions, as any other party to this Agreement shall request for the purpose of carrying
out the intent of this Agreement, including without limitation in order to carry out or
further evidence the assignment and transfer of all of QIreland’s right, title and
interest in, to and under the Distribution Agreement to the Buyer. 



        (3)
This Agreement shall be binding upon the parties hereto and their successors and assigns
and shall inure to the benefit of such parties and their permitted successors and
assigns. This Agreement is also intended for the benefit of the Buyer, and the Buyer is
an intended third-party beneficiary of this Agreement. 



        (4)
This Agreement may be executed in any number of counterparts, each of which when executed
and delivered shall be deemed to be an original and all of which counterparts taken
together should constitute one and the same instrument. The exchange of copies of this
Agreement and of executed signature pages by facsimile transmission or by email
transmission in portable digital format, or similar format, shall constitute effective
execution and delivery of 





	 	
2	 













this Agreement. Signatures of the
parties transmitted by facsimile, or by email in portable digital or similar format shall
be deemed to be their original signatures for all purposes. 



        (5)
Each party to this Agreement represents and warrants to the other party that: (a) it is
duly organized, validly existing, and in good standing under the laws of the jurisdiction
in which it is organized, with full corporate power and authority to execute, deliver and
perform this Agreement; and (b) this Agreement constitutes the legal, valid and binding
obligation of it, enforceable against it in accordance with the terms of this Agreement. 



        (6)
In consideration for Par consenting to the assignment and transfer of the Distribution
Agreement to Buyer and agreeing to the other matters set forth in this Agreement,
Quintiles agrees to pay, either directly or through an affiliate, to Par a fee of  ***  within three (3) business days after the
date of the closing of the Sale. 



[signature page follows]  





	 	
3	 













[Signature page to
Consent and Agreement]  



        IN
WITNESS WHEREOF, the parties hereto have duly executed and delivered this Agreement as of
the date first set forth above. 



	 	 
       PAR PHARMACEUTICAL,
        INC. 

       

    
	 	By:	
      /s/ Dennis O’Conner
      


      Name: Dennis O’Conner
      

      Title: VP - CFO 
	 	 	
       

       

    
	 	
      QUINTILES IRELAND LIMITED
        

       

    
	 	By:	 /s/ Marie
      Kenny 

      
      

      Name: Marie Kenny 

      Title: Director